InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

- Current share price for ILA : $0.450

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$133 FDA agrees Animal Rule pathway and PRV eligibility 17 Nov 2025 9:27AM $0.425 $0.450 risen by 5.88%
$133 Change of registered address 14 Nov 2025 8:53AM $0.425 $0.450 risen by 5.88%
$133 Webinar - FDA response to Galidesivir program 13 Nov 2025 2:34PM $0.425 $0.450 risen by 5.88%
$133 Trading Halt 13 Nov 2025 9:12AM $0.425 $0.450 risen by 5.88%
$133 Change of Director's Interest Notice - DF, JC & CN 13 Nov 2025 8:30AM $0.425 $0.450 risen by 5.88%
$133 Notification regarding unquoted securities - ILA 13 Nov 2025 8:24AM $0.425 $0.450 risen by 5.88%
$133 Change of Director's Interest Notice - CN 5 Nov 2025 9:10AM $0.430 $0.450 risen by 4.65%
$133 Change of Director's Interest Notice - DF 5 Nov 2025 9:07AM $0.430 $0.450 risen by 4.65%
$133 Cleansing Notice 30 Oct 2025 9:11AM $0.395 $0.450 risen by 13.92%
$133 Application for quotation of securities - ILA 30 Oct 2025 9:09AM $0.395 $0.450 risen by 13.92%
$133 Quarterly Appendix 4C and Activities Report 30 Oct 2025 9:02AM $0.395 $0.450 risen by 13.92%
$133 FDA confirms response timing for Galidesivir 22 Oct 2025 9:33AM $0.390 $0.450 risen by 15.38%
$133 Cleansing Notice 17 Oct 2025 9:13AM $0.370 $0.450 risen by 21.62%
$133 Application for quotation of securities - ILA 17 Oct 2025 9:10AM $0.370 $0.450 risen by 21.62%
$133 Results of AGM 9 Oct 2025 1:24PM $0.410 $0.450 risen by 9.76%
$133 Notification regarding unquoted securities - ILA 3 Oct 2025 8:46AM $0.445 $0.450 risen by 1.12%
$133 US FDA Type C meeting briefing document submitted 29 Sep 2025 8:29AM $0.410 $0.450 risen by 9.76%
$133 FDA Meeting request granted 19 Sep 2025 9:29AM $0.365 $0.450 risen by 23.29%
$133 Investor webinar 18 Sep 2025 9:06AM $0.355 $0.450 risen by 26.76%
$133 Investor presentation - Galidesivir update 17 Sep 2025 9:53AM $0.295 $0.450 risen by 52.54%
$133 Cleansing Notice 9 Sep 2025 8:29AM $0.300 $0.450 risen by 50%
$133 Application for quotation of securities - ILA 9 Sep 2025 8:29AM $0.300 $0.450 risen by 50%
$133 Letter to Shareholders, Notice of AGM & Proxy Form 5 Sep 2025 9:44AM $0.270 $0.450 risen by 66.67%
$133 FDA meeting request lodged for Galidesivir 1 Sep 2025 8:45AM $0.220 $0.450 risen by 104.55%
$133 FDA meeting request lodged for Galidesivir 1 Sep 2025 8:45AM $0.220 $0.450 risen by 104.55%

51 - 75 of 436 results

Page 3 of 18

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.